Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.

[1]  M. Sydes,et al.  Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data , 2020, The Lancet.

[2]  N. Magné,et al.  Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. , 2019, The Lancet. Oncology.

[3]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[4]  D. Elashoff,et al.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] , 2019, BMC Cancer.

[5]  N. Nickols,et al.  The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[6]  A. Kishan,et al.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning , 2017, The Journal of Nuclear Medicine.

[7]  Issam El Naqa,et al.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. , 2010, International journal of radiation oncology, biology, physics.